Biotech 2003

Fusing Science, Technology, and Business Leadership

CED, along with the North Carolina Biotechnology Center, the North Carolina Biosciences Organization (NCBIO) and the Biotechnology Industry Organization (BIO), hosted Biotech 2003 on May 21. Over 800 people participated in the 12th annual conference, which spotlighted the state’s role as a global player in life sciences and offered insight into the future of biotechnology.

Biotech 2003 included eight interactive panels discussing biotechnology trends such as DNA research, creative financing, and international partnerships. During lunch at the conference, Durham-based Trimeris, a biotech company spun out of research at Duke University, was recognized for its anti-HIV drug FUZEON, which recently received FDA approval.

In addition, Biotech 2003 featured keynote remarks from industry and government leaders. Mary Tanner, senior managing director of the Investment Banking/Healthcare Group of Bear Stearns & Co., Inc, discussed biotech and pharmaceutical stock market trends. Steve Burrill, CEO and founder of San Francisco-based Burrill & Company, highlighted investment trends guiding future activity in biotechnology. North Carolina Governor Mike Easley, who commemorated the day’s events by proclaiming May 21 “Biotech Day,” spoke of the industry’s importance to North Carolina’s economic future. Easley said he would work to ensure funding for biomanufacturing job training programs in the state.

Conference Co-chairs:
Helga Leftwich, Hutchison & Mason PLLC
Brent Keating, RBC Centura

CED Conferences: